Not provided
Not provided
Not provided
Not provided
not enough patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Boston Scientific Corporation | INDUSTRY |
Deep brain stimulation (DBS) is an established treatment for advanced complicated Parkinson's disease (PD). Several controlled randomized studies have given proof of an advantage for operated patients as compared to medically treated patients in terms of motor outcome, activities of daily living and health status. However these studies have addressed mostly stimulation of the subthalamic nucleus (STN). GPi stimulation has not been compared to best medical treatment (BMT) in a prospective randomized controlled trial in patients with complicated PD who are not good candidates for STN stimulation. The investigators aim assessing GPi-DBS in patients with PD who have contraindications for STN-DBS.
The indication and excellent therapeutic effects of STN stimulation have been sufficiently proven in advanced PD, and the contraindications for this treatment are rather well established. Also, the observation that patients fulfilling the "STN-profile" but who had been operated for pallidal DBS and lost part of the treatment's benefit over time, improved when stimulated later in the STN (instead of the GPi) shows that patients qualifying for STN-DBS do not have as good a result with GPi-DBS.
GPi stimulation may be used in patients who do not qualify for STN stimulation. Especially postural instability, age over 70 years, and mild to moderate cognitive deficits are commonly considered to be exclusion criteria for STN stimulation but not for GPi stimulation. Therefore, the investigators propose a prospective randomized controlled trial of GPi stimulation in patients with PD and motor complications who have relative or absolute contraindications for STN stimulation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GPi DBS and best medical treatment | Experimental |
| |
| Best medical treatment | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT) | Procedure | Patients in the GPi group will be implanted with DBS-electrodes within 6 weeks after randomisation. The stimulation parameters and the medical treatment are adjusted for optimal control of motor and non-motor signs and symptoms according to published guidelines using a specified algorithm. The stimulation parameters are recorded at the beginning and at the end of each post-surgical assessment. Best medical treatment is applied in combination with GPi-DBS. |
| Measure | Description | Time Frame |
|---|---|---|
| Difference of change of the score of the Parkinson's disease questionnaire 39 (PDQ-39-SI) from baseline to follow-up between the two treatment groups. | Baseline and 5 months +/- 1 month | |
| Difference of change in number of hours per day spent in motor "on" without troublesome dyskinesia from baseline to follow-up between the two treatment groups. | Baseline and 5 months +/- 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Difference of change of the score of the MDS-UPDRS part III (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, part III) from baseline to follow up between the two trial groups. | Baseline and 5 months +/- 1 month | |
| Difference of change of the score of the MDS-UPDRS part IV (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, part IV) (MDS-UPDRS) from baseline to follow up between the two trial groups. |
Not provided
Inclusion Criteria:
Parkinson's disease according to the UKBB criteria, with the exception that familial forms of otherwise typical parkinsonian syndromes may also be included
motor complications of dopaminergic medication (dyskinesia or motor fluctuations or both) that are at least moderately bothersome to the patient [on a scale of 5 possible levels: not at all / mildly / moderately / severely / extremely bothersome]
Presence of at least one of the following absolute exclusion criteria for STN stimulation:
or presence of at least two of the following relative exclusion criteria for STN stimulation:
Complete baseline PDQ-39-SI and patient diary available
written informed consent
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael Schüpbach, PD Dr. med | Inselspital University Hospital Bern | Principal Investigator |
| Ines Debove, Dr. med | Inselspital University Hospital Bern | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Inselspital University Hospital Bern | Bern | 3010 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Best medical treatment | Procedure | Patients will receive optimized medical treatment according to published evidence based guidelines. |
|
| Baseline and 5 months +/- 1 month |
| Difference of change in number of hours per day spent in motor "on" with troublesome dyskinesia from baseline to follow-up between the two treatment groups. | 5 months +/- 1 months |
| ID | Term |
|---|---|
| D002493 | Central Nervous System Diseases |
| D001480 | Basal Ganglia Diseases |
| D009069 | Movement Disorders |
| D019636 | Neurodegenerative Diseases |
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
| D001927 | Brain Diseases |
| D020734 | Parkinsonian Disorders |
| D000080874 | Synucleinopathies |
Not provided
Not provided
| ID | Term |
|---|---|
| D046690 | Deep Brain Stimulation |
| ID | Term |
|---|---|
| D004599 | Electric Stimulation Therapy |
| D013812 | Therapeutics |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided